Hepatocolic fistula in hepatocellular carcinoma treated with atezolizumab-bevacizumab: a case report on successful salvage hepatectomy

阿特珠单抗-贝伐珠单抗治疗肝细胞癌并发肝结肠瘘:一例成功行挽救性肝切除术的病例报告

阅读:2

Abstract

Combined treatment with atezolizumab (ATZ) and bevacizumab (BV) is the first-line therapy for unresectable advanced hepatocellular carcinoma (HCC). We report a rare case of hepatocolic fistula during ATZ + BV therapy, successfully treated with salvage hepatectomy. A 72-year-old man with advanced HCC underwent treatment with ATZ + BV. After seven cycles, he presented with abdominal pain. Imaging revealed ascites and free air, leading to an emergency laparotomy, where panperitonitis was diagnosed. Despite lavage and drainage, postoperative fever persisted. Further imaging identified a liver abscess, requiring emergency ultrasound-guided percutaneous drainage. Contrast studies confirmed a hepatocolic fistula. The patient underwent ileostomy for abscess management, followed by extended posterior sectionectomy and right hemicolectomy on Day 25. He was discharged 37 days after final surgery without complications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。